In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staphylococcus aureus |
| |
| Authors: | Saravolatz Louis D Pawlak Joan Johnson Leonard Bonilla Hector Saravolatz Louis D Fakih Mohamad G Fugelli Anders Olsen Wenche Marie |
| |
| Affiliation: | St. John Hospital and Medical Center, Detroit, Michigan, USA. louis.saravolatz@stjohn.org |
| |
| Abstract: | LTX-109 and eight other antimicrobial agents were evaluated against 155 methicillin-resistant Staphylococcus aureus (MRSA) isolates, including strains resistant to vancomycin and strains with decreased susceptibility to daptomycin and linezolid, by microdilution tests to determine MICs. Time-kill assays were performed against representative MRSA, vancomycin-intermediate S. aureus (VISA), and vancomycin-resistant S. aureus (VRSA) isolates. LTX-109 demonstrated a MIC range of 2 to 4 μg/ml and dose-dependent rapid bactericidal activity against S. aureus. This activity was not influenced by resistance to other antistaphylococcal agents. |
| |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ |
|
